collection
MENU ▼
Read by QxMD icon Read
search

Radioterapia Ca Próstata

shared collection
92 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28463149/duration-of-androgen-deprivation-in-locally-advanced-prostate-cancer-long-term-update-of-nrg-oncology-rtog-9202
#1
Colleen A F Lawton, Xiaolei Lin, Gerald E Hanks, Herbert Lepor, David J Grignon, Harmar D Brereton, Meena Bedi, Seth A Rosenthal, Kenneth L Zeitzer, Varagur M Venkatesan, Eric M Horwitz, Thomas M Pisansky, Harold Kim, Matthew B Parliament, Rachel Rabinovitch, Mack Roach, Young Kwok, James J Dignam, Howard M Sandler
PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#2
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28433413/stereotactic-ablative-radiotherapy-in-the-treatment-of-low-and-intermediate-risk-prostate-cancer-is-there-an-optimal-dose
#3
Joelle Helou, Laura D'Alimonte, Harvey Quon, Andrea Deabreu, Kristina Commisso, Patrick Cheung, William Chu, Alexandre Mamedov, Melanie Davidson, Ananth Ravi, Andrew Loblaw
PURPOSE: To investigate if stereotactic ablative radiotherapy (SABR) dose is associated with PSA at 3years (PSA3y) in the treatment of localized prostate cancer and to explore predictors of late genitourinary (GU) toxicity. MATERIALS AND METHODS: Three prospective trials of SABR were undertaken at our institution: 1) 35Gy/5 fractions/29days; 2) 40Gy/5 fractions/29days; 3) 40Gy/5 fractions/11 or 29days. PSA3y was analyzed as a continuous variable. Toxicity was defined as the worst new toxicity and assessed using the radiation therapy oncology group (RTOG) late morbidity scheme...
April 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28434799/improved-outcomes-with-dose-escalation-in-localized-prostate-cancer-treated-with-precision-image-guided-radiotherapy
#4
Hamid Raziee, Fabio Y Moraes, Jure Murgic, Melvin L K Chua, Melania Pintilie, Peter Chung, Cynthia Ménard, Andrew Bayley, Mary Gospodarowicz, Padraig Warde, Tim Craig, Charles Catton, Robert G Bristow, David A Jaffray, Alejandro Berlin
BACKGROUND AND PURPOSE: Dose-escalated radiotherapy (DE) improves outcomes in localized prostate cancer (PCa). The impact of DE in the context of image-guided radiotherapy (IGRT) remains unknown. Herein, we determined outcomes of three sequential cohorts treated with progressive DE-IGRT. MATERIALS AND METHODS: We analyzed data from 1998 to 2012. Patients treated with radical radiotherapy were included, with three sequential institutional schedules: (A) 75.6Gy, (B) 79...
April 20, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28422278/decipher-test-impacts-decision-making-among-patients-considering-adjuvant-and-salvage-treatment-after-radical-prostatectomy-interim-results-from-the-multicenter-prospective-pro-impact-study
#5
John L Gore, Marguerite du Plessis, María Santiago-Jiménez, Kasra Yousefi, Darby J S Thompson, Lawrence Karsh, Brian R Lane, Michael Franks, David Y T Chen, Mark Bandyk, Fernando J Bianco, Gordon Brown, William Clark, Adam S Kibel, Hyung L Kim, William Lowrance, Murugesan Manoharan, Paul Maroni, Scott Perrapato, Paul Sieber, Edouard J Trabulsi, Robert Waterhouse, Elai Davicioni, Yair Lotan, Daniel W Lin
BACKGROUND: Patients with prostate cancer and their providers face uncertainty as they consider adjuvant radiotherapy (ART) or salvage radiotherapy (SRT) after undergoing radical prostatectomy. The authors prospectively evaluated the impact of the Decipher test, which predicts metastasis risk after radical prostatectomy, on decision making for ART and SRT. METHODS: A total of 150 patients who were considering ART and 115 who were considering SRT were enrolled. Providers submitted a management recommendation before processing the Decipher test and again at the time of receipt of the test results...
April 19, 2017: Cancer
https://www.readbyqxmd.com/read/28377721/prostate-cancer-and-aspirin-use-synopsis-of-the-proposed-molecular-mechanisms
#6
REVIEW
Nadeem Bilani, Hisham Bahmad, Wassim Abou-Kheir
Background: Prostate cancer (PCa) is a critical health burden, impacting the morbidity and mortality of millions of men around the world. Most of the patients with PCa have their disease at first sensitive to androgen deprivation treatments, but later they develop resistance to therapy and eventually die of metastatic castration-resistant prostate cancer (CRPC). Although the newly developed anti-androgen therapies are effectively alleviating symptoms and prolonging lives of patients, there are still no curable treatments for CRPC...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28417429/approach-to-androgen-deprivation-in-the-prostate-cancer-patient-with-pre-existing-cardiovascular-disease
#7
REVIEW
Alyssa K Greiman, Thomas E Keane
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events, especially in those receiving gonadotropin-releasing hormone (GnRH) agonists compared to GnRH antagonists. We review the body of literature reporting the association of ADT and cardiovascular morbidity, and discuss the proposed mechanism of cardiovascular disease due to ADT including metabolic changes that may promote atherosclerosis and local hormonal effects that may increase plaque rupture and thrombosis...
June 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28341241/high-dose-rate-brachytherapy-as-monotherapy-for-localised-prostate-cancer-review-of-the-current-status
#8
N Tselis, P Hoskin, D Baltas, V Strnad, N Zamboglou, C Rödel, G Chatzikonstantinou
The aim of this article is to review and present the published data on high dose rate (HDR) brachytherapy as monotherapy in the treatment of localised prostate cancer. A search and review of the literature was carried out on PubMed and MedLine using the medical subject headings 'high-dose-rate, brachytherapy, prostate cancer, monotherapy' as search terms. The search yielded more than 100 articles and abstracts published between 2000 and 2016. Only original clinical data on HDR monotherapy reporting oncological outcomes were included...
March 22, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28392836/androgen-deprivation-therapy-in-the-treatment-of-locally-advanced-nonmetastatic-prostate-cancer-practical-experience-and-a-review-of-the-clinical-trial-evidence
#9
REVIEW
Fouad Aoun, Ali Bourgi, Elias Ayoub, Elie El Rassy, Roland van Velthoven, Alexandre Peltier
Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice for those patients. These variables are summarized and discussed in detail. High radiation doses to the prostate are essential to achieve good local control in patients with high-risk nonmetastatic disease. Addition of androgen deprivation therapy (ADT) to radiation therapy has significantly improved overall survival and cancer-specific survival compared with radiation therapy alone without significantly increasing toxicity...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28204918/androgen-deprivation-therapy-and-the-risk-of-parkinsonism-in-men-with-prostate-cancer
#10
James W S Young, Rinku Sutradhar, Jagadish Rangrej, Connie Marras, Neil Fleshner, Shabbir M H Alibhai
PURPOSE: Case reports and anecdotal experiences suggest that some men develop parkinsonism after initiating androgen deprivation therapy (ADT) for the treatment of prostate cancer, possibly due to neurophysiological effects of changes in testosterone and/or estrogen. We hypothesized that ADT would increase the risk of parkinsonism. METHODS: Using linked administrative databases in Ontario, Canada, men age 40 or older with prostate cancer on continuous ADT for at least 6 months or who underwent bilateral orchiectomy (n = 38,931) were matched 1:1 with men with prostate cancer who had never received ADT...
February 15, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28274241/salvage-prostate-re-irradiation-using-high-dose-rate-brachytherapy-or-focal-stereotactic-body-radiotherapy-for-local-recurrence-after-definitive-radiation-therapy
#11
Aurélie Mbeutcha, Laurent Chauveinc, Pierre-Yves Bondiau, Marie-Eve Chand, Matthieu Durand, Daniel Chevallier, Jean Amiel, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi
BACKGROUND: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the feasibility of a prostate re-irradiation after definitive radiation therapy failure. Two modalities were investigated: high-dose-rate brachytherapy (HDRB) on whole prostate gland and focal stereotactic radiotherapy (SBRT) using CyberKnife® linac...
March 9, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28344813/the-modern-role-of-androgen-deprivation-therapy-in-the-management-of-localised-and-locally-advanced-prostate-cancer
#12
Charlotte Gunner, Aziz Gulamhusein, Derek J Rosario
INTRODUCTION: Approximately 50% of men diagnosed with prostate cancer will be exposed to androgen deprivation therapy (ADT) at some stage. The role of ADT in the management of metastatic disease has long been recognised, and its place in the management of localised and locally advanced disease has become clearer in the past few years. Nevertheless, concerns remain that some men might not benefit from ADT in earlier-stage disease. The purpose of the current article is to provide a brief narrative review of the role of ADT as part of a strategy of treatment with curative intent, concentrating mainly on key recent developments in the area...
December 2016: Journal of Clinical Urology
https://www.readbyqxmd.com/read/27986207/biomarkers-of-outcome-in-patients-with-localized-prostate-cancer-treated-with-radiotherapy
#13
REVIEW
William A Hall, Colleen A Lawton, Ashesh B Jani, Alan Pollack, Felix Y Feng
Prostate cancer represents one of the most prevalent malignancies in the world. Although subsets of prostate cancer are aggressive and can metastasize, it is also evident that most patients harbor indolent disease. Although current risk-stratification approaches use both clinical and pathologic factors, it is clear that biomarkers can be used to improve on these approaches. In this article, we review the currently published literature on prostate cancer molecular biomarkers, primarily in the context of radiation therapy, focusing on those found in serum, plasma, urine, and within the tumor biopsy itself...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986208/advances-in-prostate-cancer-magnetic-resonance-imaging-and-positron-emission-tomography-computed-tomography-for-staging-and-radiotherapy-treatment-planning
#14
REVIEW
Drew Moghanaki, Baris Turkbey, Neha Vapiwala, Behfar Ehdaie, Steven J Frank, Patrick W McLaughlin, Mukesh Harisinghani
Conventional prostate cancer staging strategies have limited accuracy to define the location, grade, and burden of disease. Evaluations have historically relied upon prostate-specific antigen levels, digital rectal examinations, random systematic biopsies, computed tomography, pelvic lymphadenectomy, or (99m)technetium methylene diphosphonate bone scans. Today, risk-stratification tools incorporate these data in a weighted format to guide management. However, the limitations and potential consequences of their uncertainties are well known...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986209/prostate-cancer-genetics-variation-by-race-ethnicity-and-geography
#15
REVIEW
Timothy R Rebbeck
Prostate cancer rates vary substantially by race, ethnicity, and geography. These disparities can be explained by variation in access to screening and treatment, variation in exposure to prostate cancer risk factors, and variation in the underlying biology of prostate carcinogenesis (including genomic propensity of some groups to develop biologically aggressive disease). It is clear that access to screening and access to treatment are critical influencing factors of prostate cancer rates; yet, even among geographically diverse populations with similar access to care (eg, low- and medium-income countries), African descent men have higher prostate cancer rates and poorer prognosis...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986210/emerging-technologies-and-techniques-in-radiation-therapy
#16
REVIEW
William J Magnuson, Amandeep Mahal, James B Yu
The past decade has brought an improved ability to precisely target and deliver radiation as well as other focal prostate-directed therapy. Stereotactic body radiotherapy (SBRT), proton beam radiation, high-dose-rate (HDR) brachytherapy, as well as nonradiotherapy treatments such as cryoablation and high-intensity focused ultrasound are several therapeutic modalities that have been investigated for the treatment of prostate cancer in an attempt to reduce toxicity while improving cancer control. However, high-risk prostate cancer requires a comprehensive treatment of the prostate as well as areas at risk for cancer spread...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986211/optimization-of-the-radiation-management-of-high-risk-prostate-cancer
#17
REVIEW
Paul L Nguyen
Radiation and androgen-deprivation therapy (ADT) are mainstays of treatment for men with high-risk prostate cancer. High-risk disease is heterogeneous and subcategories of "favorable" high risk and very high risk can identify subgroups with particularly good or poor prognosis to help personalize treatment. Overall, randomized trials show that the combination of radiation and ADT improves survival when compared with either by itself. The optimum duration of ADT remains controversial, but for most healthy men with aggressive disease, approximately 2-3 years of ADT is well supported by the literature...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986212/postoperative-radiation-after-radical-prostatectomy
#18
REVIEW
Eric C Ko, Anthony L Michaud, Richard K Valicenti
A total of 3 randomized clinical trials have demonstrated a significant clinical benefit with adjuvant radiation in patients with high-risk prostate cancer after radical prostatectomy, with each showing improved biochemical control outcomes, and one trial (SWOG 8794) also demonstrating increased overall survival. How broadly these results have informed clinical practice has evolved over time, given the widespread availability of ultrasensitive prostate-specific antigen level testing and increased awareness that the high-risk patients are not a uniform cohort...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/27986215/beyond-just-androgen-deprivation-therapy-novel-therapies-combined-with-radiation
#19
REVIEW
Oliver Sartor, Brian Lewis
External beam radiation therapy (EBRT) combined with androgen deprivation are standard of care for selected patients with prostate cancer. In recent years, multiple therapies have been experimentally combined with EBRT either concomitantly or adjuvantly. These therapies include chemotherapies, immunotherapies, and novel hormones. In addition to EBRT, clinical trials with radiopharmaceuticals are planned or have been performed with concomitant chemotherapy, immunotherapies, novel hormones, and inhibitors of DNA damage repair...
January 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28267451/imaging-of-prostate-cancer-using-18-f-choline-pet-computed-tomography
#20
REVIEW
Marina Hodolič
(18)F-fluorocholine (FCH) PET/computed tomography (CT) is a valuable imaging modality in prostate cancer disease. Probably, its main role is restaging of patients with biochemical recurrence after radical prostatectomy or external beam radiotherapy. (18)F-FCH PET/CT is strengthening its position in the initial staging, biopsy target definition, radiotherapy planning, and therapy monitoring. Gleason score and prostate-specific antigen value, doubling time, and velocity can influence positivity of (18)F-FCH PET/CT...
April 2017: PET Clinics
label_collection
label_collection
7601
1
2
2017-03-28 23:23:20
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"